We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

86 hedge funds and large institutions have $26.8M invested in Tetraphase Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 32 increasing their positions, 22 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 22

7% less funds holding

Funds holding: 9286 (-6)

30% less call options, than puts

Call options by funds: $26K | Put options by funds: $37K

43% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 14

58% less capital invested

Capital invested by funds: $63.4M → $26.8M (-$36.6M)

Holders
86
Holders Change
-6
Holders Change %
-6.52%
% of All Funds
1.92%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
32
Reduced
22
Closed
14
Calls
$26K
Puts
$37K
Net Calls
-$11K
Net Calls Change
-$253K
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
$186K +$69K +1,765 +27%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$185K
Charles Schwab
28
Charles Schwab
California
$176K +$76.8K +1,965 +34%
Bank of America
29
Bank of America
North Carolina
$161K +$16.8K +429 +6%
TA
30
Teachers Advisors
New York
$140K +$66.3K +1,696 +38%
Citadel Advisors
31
Citadel Advisors
Florida
$136K -$115K -2,937 -33%
AIM
32
Alambic Investment Management
California
$130K +$53.1K +1,359 +31%
BCM
33
Bridgeway Capital Management
Texas
$124K -$147K -3,750 -41%
EDRH
34
Edmond de Rothschild Holding
Switzerland
$124K
Axa
35
Axa
France
$112K -$229K -5,867 -54%
TCIM
36
TIAA CREF Investment Management
New York
$112K
GF
37
Gabelli Funds
New York
$111K +$3.91K +100 +2%
Millennium Management
38
Millennium Management
New York
$110K -$882K -22,543 -82%
ARTA
39
A.R.T. Advisors
New York
$107K -$9.15K -234 -5%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$102K +$23.4K +598 +15%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$82K +$41.3K +1,055 +41%
Walleye Trading
42
Walleye Trading
New York
$82K +$141K +3,614 New
DCC
43
Dow Chemical Company
Michigan
$73K
QSS
44
Quantitative Systematic Strategies
Florida
$71K +$80.5K +2,058 +192%
SG Americas Securities
45
SG Americas Securities
New York
$69K +$120K +3,065 New
AllianceBernstein
46
AllianceBernstein
Tennessee
$63K
State of Wisconsin Investment Board
47
State of Wisconsin Investment Board
Wisconsin
$62K +$52.2K +1,335 +95%
Invesco
48
Invesco
Georgia
$61K +$15.8K +405 +18%
GI
49
GAMCO Investors
Connecticut
$57K +$29.3K +750 +43%
MCM
50
Manchester Capital Management
Vermont
$53K

TTPH Hedge Fund Activity: Q4 2018 in Review

86 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q4 2018, worth a combined $26.8M — down 58% from $63.4M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of TTPH and 8 opened new positions — a net loss of 6 holders — while 22 trimmed existing stakes and 32 added.

The largest buyer was Renaissance Technologies, adding an estimated $3.04M. The largest seller was Vanguard Group, cutting an estimated $2.24M.

  • 86 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q4 2018, down from 92 in Q3 2018.
  • Funds reported $26.8M of Tetraphase Pharmaceuticals, Inc. stock for Q4 2018, down 58% quarter-over-quarter.
  • 8 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q4 2018 and 14 closed out, a net change of -6 holders.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q4 2018 was Renaissance Technologies, an estimated $3.04M added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q4 2018 was Vanguard Group, an estimated $2.24M sold.

Based on aggregated 13F filings for Q4 2018.